Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...

Utrophin increase in muscle cells after transcriptional adaptation normalises cell function in Duchenne muscular dystrophy ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Abstract Title: Safety and Efficacy of DYNE-101 in Adults with DM1: Phase 1/2 ACHIEVE Trial Data Date and Time: Wednesday, March 19, at 12:30-12:45 p.m. CT Presenter: James Lilleker M.D., Neurologist, ...

The colorful threads in this image are muscle fibers. This spotted rainbow illustrates a potential gene therapy approach to treating Duchenne muscular dystrophy (DMD) – a rare, debilitating, and fatal ...

The Swiss biopharma company said the deal with the German National Association of Statutory Health Insurance Funds (GKV-SV) ...

Around 13% of DMD patients respond to exon 51 skipping, but PepGen reckons other drugs in its pipeline will address mutations that are central to around 35% of all cases of the disease.

Duchenne muscular dystrophy (DMD) is a rare genetic disorder that is characterised by progressive muscle degeneration and weakness, and is caused by mutations in the dystrophin gene. Currently ...

Pratteln, Switzerland Friday, February 14, 2025, 15:00 Hrs [IST] ...